Polatuzumab vedotin

Overview

Diagram of Antibody-Drug Conjugates (ADCs) like Polatuzumab vedotin

Polatuzumab vedotin is a monoclonal antibody used in the treatment of certain types of cancer, specifically B-cell non-Hodgkin lymphoma. It is an example of an antibody-drug conjugate (ADC), which combines the targeting capabilities of a monoclonal antibody with the cancer-killing ability of a cytotoxic drug.

Mechanism of Action

Polatuzumab vedotin targets the CD79b protein, which is expressed on the surface of B-cells. The monoclonal antibody component of polatuzumab vedotin binds to CD79b, allowing the ADC to deliver its cytotoxic payload directly to the cancerous B-cells. The cytotoxic agent in polatuzumab vedotin is monomethyl auristatin E (MMAE), a potent inhibitor of microtubule polymerization, which leads to cell cycle arrest and apoptosis of the targeted cells.

Clinical Use

Polatuzumab vedotin is primarily used in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), often in combination with other chemotherapeutic agents such as bendamustine and rituximab. It is administered intravenously and is typically reserved for patients who have not responded to other treatments.

Side Effects

Common side effects of polatuzumab vedotin include peripheral neuropathy, fatigue, nausea, and diarrhea. More serious adverse effects can include neutropenia, thrombocytopenia, and anemia. Patients receiving polatuzumab vedotin require regular monitoring of blood counts and neurological status.

Development and Approval

Polatuzumab vedotin was developed by Genentech, a member of the Roche Group. It received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2019 for use in combination with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory DLBCL.

Related Pages

• Monoclonal antibody therapy
• Antibody-drug conjugate
• Diffuse large B-cell lymphoma
• Cancer treatment